Cargando…

Peptide Inhibitors of the Interaction of the SARS-CoV-2 Receptor-Binding Domain with the ACE2 Cell Receptor

Computer simulation has been used to identify peptides that mimic the natural target of the SARS-CoV-2 coronavirus spike (S) protein, the angiotensin-converting enzyme type 2 (ACE2) cell receptor. Based on the structure of the complex of the protein S receptor-binding domain (RBD) and ACE2, the desi...

Descripción completa

Detalles Bibliográficos
Autores principales: Bibilashvili, R. Sh., Sidorova, M. V., Dudkina, U. S., Palkeeva, M. E., Molokoedov, A. S., Kozlovskaya, L. I., Egorov, A. M., Ishmukhametov, A. A., Parfyonova, E.V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Pleiades Publishing 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8562373/
https://www.ncbi.nlm.nih.gov/pubmed/34745440
http://dx.doi.org/10.1134/S199075082104003X
_version_ 1784593246554423296
author Bibilashvili, R. Sh.
Sidorova, M. V.
Dudkina, U. S.
Palkeeva, M. E.
Molokoedov, A. S.
Kozlovskaya, L. I.
Egorov, A. M.
Ishmukhametov, A. A.
Parfyonova, E.V.
author_facet Bibilashvili, R. Sh.
Sidorova, M. V.
Dudkina, U. S.
Palkeeva, M. E.
Molokoedov, A. S.
Kozlovskaya, L. I.
Egorov, A. M.
Ishmukhametov, A. A.
Parfyonova, E.V.
author_sort Bibilashvili, R. Sh.
collection PubMed
description Computer simulation has been used to identify peptides that mimic the natural target of the SARS-CoV-2 coronavirus spike (S) protein, the angiotensin-converting enzyme type 2 (ACE2) cell receptor. Based on the structure of the complex of the protein S receptor-binding domain (RBD) and ACE2, the design of chimeric molecules consisting of two 22–23-mer peptides linked to each other by disulfide bonds was carried out. The chimeric molecule X1 was a disulfide dimer, in which terminal cysteine residues in the precursor molecules h1 and h2 were connected by the S-S bond. In the chimeric molecule X2, the disulfide bond was located in the middle of each precursor peptide molecule. The precursors h1 and h2 mimic amino acid sequences of α1- and α2-helices of the ACE2 extracellular peptidase domain, respectively, keeping intact most of the amino acid residues involved in the interaction with RBD. The aim of the work was to evaluate the binding efficiency of chimeric molecules and their constituent peptides with RBD (particularly in dependence of the middle and terminal methods of fixing the initial peptides h1 and h2). The proposed polypeptides and chimeric molecules were synthesized by chemical methods, purified to 95–97% purity, and characterized by HPLC and MALDI-TOF mass spectrometry. Binding of these peptides to the SARS-CoV-2 RBD was evaluated by microthermophoresis with recombinant domains corresponding in sequence to the original Chinese (GenBank ID NC_045512.2) and the British (B. 1.1.7, GISAID EPI_ISL_683466) variants. The original RBD of the Chinese variant bound to three synthesized peptides: linear h2 and both chimeric variants. Chimeric peptides were also bound to the RBD of the British variant. The antiviral activity of the proposed peptides was evaluated in Vero cell line.
format Online
Article
Text
id pubmed-8562373
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Pleiades Publishing
record_format MEDLINE/PubMed
spelling pubmed-85623732021-11-03 Peptide Inhibitors of the Interaction of the SARS-CoV-2 Receptor-Binding Domain with the ACE2 Cell Receptor Bibilashvili, R. Sh. Sidorova, M. V. Dudkina, U. S. Palkeeva, M. E. Molokoedov, A. S. Kozlovskaya, L. I. Egorov, A. M. Ishmukhametov, A. A. Parfyonova, E.V. Biochem Mosc Suppl B Biomed Chem Article Computer simulation has been used to identify peptides that mimic the natural target of the SARS-CoV-2 coronavirus spike (S) protein, the angiotensin-converting enzyme type 2 (ACE2) cell receptor. Based on the structure of the complex of the protein S receptor-binding domain (RBD) and ACE2, the design of chimeric molecules consisting of two 22–23-mer peptides linked to each other by disulfide bonds was carried out. The chimeric molecule X1 was a disulfide dimer, in which terminal cysteine residues in the precursor molecules h1 and h2 were connected by the S-S bond. In the chimeric molecule X2, the disulfide bond was located in the middle of each precursor peptide molecule. The precursors h1 and h2 mimic amino acid sequences of α1- and α2-helices of the ACE2 extracellular peptidase domain, respectively, keeping intact most of the amino acid residues involved in the interaction with RBD. The aim of the work was to evaluate the binding efficiency of chimeric molecules and their constituent peptides with RBD (particularly in dependence of the middle and terminal methods of fixing the initial peptides h1 and h2). The proposed polypeptides and chimeric molecules were synthesized by chemical methods, purified to 95–97% purity, and characterized by HPLC and MALDI-TOF mass spectrometry. Binding of these peptides to the SARS-CoV-2 RBD was evaluated by microthermophoresis with recombinant domains corresponding in sequence to the original Chinese (GenBank ID NC_045512.2) and the British (B. 1.1.7, GISAID EPI_ISL_683466) variants. The original RBD of the Chinese variant bound to three synthesized peptides: linear h2 and both chimeric variants. Chimeric peptides were also bound to the RBD of the British variant. The antiviral activity of the proposed peptides was evaluated in Vero cell line. Pleiades Publishing 2021-11-02 2021 /pmc/articles/PMC8562373/ /pubmed/34745440 http://dx.doi.org/10.1134/S199075082104003X Text en © Pleiades Publishing, Ltd. 2021, ISSN 1990-7508, Biochemistry (Moscow), Supplement Series B: Biomedical Chemistry, 2021, Vol. 15, No. 4, pp. 274–280. © Pleiades Publishing, Ltd., 2021.Russian Text © The Author(s), 2021, published in Biomeditsinskaya Khimiya. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Article
Bibilashvili, R. Sh.
Sidorova, M. V.
Dudkina, U. S.
Palkeeva, M. E.
Molokoedov, A. S.
Kozlovskaya, L. I.
Egorov, A. M.
Ishmukhametov, A. A.
Parfyonova, E.V.
Peptide Inhibitors of the Interaction of the SARS-CoV-2 Receptor-Binding Domain with the ACE2 Cell Receptor
title Peptide Inhibitors of the Interaction of the SARS-CoV-2 Receptor-Binding Domain with the ACE2 Cell Receptor
title_full Peptide Inhibitors of the Interaction of the SARS-CoV-2 Receptor-Binding Domain with the ACE2 Cell Receptor
title_fullStr Peptide Inhibitors of the Interaction of the SARS-CoV-2 Receptor-Binding Domain with the ACE2 Cell Receptor
title_full_unstemmed Peptide Inhibitors of the Interaction of the SARS-CoV-2 Receptor-Binding Domain with the ACE2 Cell Receptor
title_short Peptide Inhibitors of the Interaction of the SARS-CoV-2 Receptor-Binding Domain with the ACE2 Cell Receptor
title_sort peptide inhibitors of the interaction of the sars-cov-2 receptor-binding domain with the ace2 cell receptor
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8562373/
https://www.ncbi.nlm.nih.gov/pubmed/34745440
http://dx.doi.org/10.1134/S199075082104003X
work_keys_str_mv AT bibilashvilirsh peptideinhibitorsoftheinteractionofthesarscov2receptorbindingdomainwiththeace2cellreceptor
AT sidorovamv peptideinhibitorsoftheinteractionofthesarscov2receptorbindingdomainwiththeace2cellreceptor
AT dudkinaus peptideinhibitorsoftheinteractionofthesarscov2receptorbindingdomainwiththeace2cellreceptor
AT palkeevame peptideinhibitorsoftheinteractionofthesarscov2receptorbindingdomainwiththeace2cellreceptor
AT molokoedovas peptideinhibitorsoftheinteractionofthesarscov2receptorbindingdomainwiththeace2cellreceptor
AT kozlovskayali peptideinhibitorsoftheinteractionofthesarscov2receptorbindingdomainwiththeace2cellreceptor
AT egorovam peptideinhibitorsoftheinteractionofthesarscov2receptorbindingdomainwiththeace2cellreceptor
AT ishmukhametovaa peptideinhibitorsoftheinteractionofthesarscov2receptorbindingdomainwiththeace2cellreceptor
AT parfyonovaev peptideinhibitorsoftheinteractionofthesarscov2receptorbindingdomainwiththeace2cellreceptor